Abstract
Influenza is an acute respiratory infection with high morbidity and non-trivial mortality, especially among high risk population groups. The course of the disease can be positively influenced by treatment with antiviral agents.
There are currently two inhibitors of viral neuraminidase used in clinical practice - oseltamivir and zanamivir, which are effective against influenza A and B and are they also well tolerated. Increasing resistance can be a problem in the future, especially against oseltamivir, resulting from more widespread and more frequent use of drugs of this class